The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus.

Fazioli, Katherine T; Rind, David M; Guzauskas, Gregory F; Hansen, Ryan N; Pearson, Steven D

Fazioli, Katherine T; Rind, David M; Guzauskas, Gregory F; Hansen, Ryan N; Pearson, Steven D.

Affiliation

Fazioli KT; Institute for Clinical and Economic Review, Boston, Massachusetts.
Rind DM; Institute for Clinical and Economic Review, Boston, Massachusetts.
Guzauskas GF; The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle.
Hansen RN; The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle.
Pearson SD; Institute for Clinical and Economic Review, Boston, Massachusetts.

J Manag Care Spec Pharm ; 26(9): 1072-1076, 2020 Sep.

Article in En | MEDLINE | ID: mdl-32857658

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptides/administration & dosage; Hypoglycemic Agents/administration & dosage; Administration, Oral; Cost-Benefit Analysis; Diabetes Mellitus, Type 2/economics; Glucagon-Like Peptide-1 Receptor/agonists; Glucagon-Like Peptides/economics; Humans; Hypoglycemic Agents/economics; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Glucagon-Like Peptides / Hypoglycemic Agents Limits: Humans Language: En Journal: J Manag Care Spec Pharm Year: 2020 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google